The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
The Chemours CompanyNYSE: CC
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin remains negative
Q2 FY2026 selling, general & admin was $0, compared with $0 a year earlier. Trailing-twelve-month selling, general & admin was $801M. Over 3 fiscal years it compounded at +4.0% a year.
Context
- Selling, general & admin amounted to 13.8% of revenue in FY2025, up 3.6 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $768.65M (-3.8%) for the fiscal year ending Dec 2026, a slowdown from the +36.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0-100.0% QoQ
- Last fiscal yearDec 2025
- $799M+36.6% YoY
- LTMJun 2026
- $801M+87.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +36.6% | -3.8% | -40.4 pp |
| 3-year CAGR | +4.0% | +1.4% | -2.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 799M USD
- Year-over-year change
- +36.6%
- 4-year CAGR
- +7.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 799M | +36.6% |
| FY2024 | 2024-12-31 | 585M | -54.7% |
| FY2023 | 2023-12-31 | 1.29B | +81.7% |
| FY2022 | 2022-12-31 | 710M | +19.9% |
| FY2021 | 2021-12-31 | 592M | — |
Selling, General & Admin vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 selling, general & admin of $801M is the 8th highest of the 19 companies compared; the peer median is $641.15M.
- Its year-over-year change of +87.6% is the highest of 19, against a peer median of +5.7%.
- Selling, general & admin amounts to 13.8% of revenue for CC, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.56B | +8.1% | +3.4% | 10.0% | |
| LTM Jun 2026 | $3.55B | +19.8% | +4.2% | 21.6% | |
| LTM Jun 2026 | $1.75B | -10.3% | +1.2% | 17.6% | |
| LTM Sep 2026 | $1.66B | -0.4% | +9.1% | 5.2% | |
| LTM Sep 2026 | $973M | +7.9% | +4.0% | 8.5% | |
| LTM Sep 2026 | $903.2M | -0.3% | -1.9% | 7.0% | |
| LTM Jun 2026 | $832M | -1.3% | +2.6% | 16.2% | |
| LTM Jun 2026 | $801M | +87.6% | +4.0% | 13.8% | |
| LTM Sep 2026 | $787M | +23.4% | +4.5% | 22.6% | |
| LTM Aug 2026 | $755.64M | +4.5% | +5.6% | 21.3% | |
| LTM Sep 2026 | $526.67M | +9.5% | +2.7% | 26.0% | |
| LTM Jun 2026 | $350.86M | +9.4% | +9.9% | 20.6% | |
| LTM Jun 2026 | $324M | +2.2% | -4.2% | 17.6% | |
| LTM Jun 2026 | $277M | +4.5% | +0.3% | 7.6% | |
| LTM Mar 2026 | $231.4M | -1.4% | +0.5% | 12.9% | |
| LTM Sep 2026 | $178.61M | +16.7% | +10.7% | 11.7% | |
| LTM Jun 2026 | $95.36M | +32.8% | +8.7% | 12.6% | |
| LTM Mar 2026 | $73.69M | -6.4% | -8.2% | 9.0% | |
| LTM Mar 2026 | $10.96M | +6.8% | +6.5% | 9.9% | |
| Peer median (excluding CC) | $641.15M | +5.7% | +3.7% | 12.8% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.